Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

QIAGEN

Qiagen is a provider of sample and assay technologies for molecular diagnostics and applied testing, including comple... read more Featured Products: More products

Download Mobile App




Host RNA Expression Diagnoses Childhood Tuberculosis

By LabMedica International staff writers
Posted on 15 May 2014
Tuberculosis (TB) is notoriously difficult to diagnose in children and when it is diagnosed, the disease is often in its late stages and has already spread to the brain and other organs, increasing the risk of death. More...


The use of genomewide ribonucleic acid (RNA) expression in host blood to distinguish tuberculosis from other diseases that are prevalent among African children with and those without human immunodeficiency virus (HIV) infection has been explored.

An international team of scientists led by those at Imperial College London (UK) analyzed more than 2,800 children from Malawi, Kenya, and South Africa. All children had been admitted to the hospital with symptoms of TB. They then established which children had proven TB and which children had been cleared of the disease. Patients were recruited between February 17, 2008, and January 27, 2011.

Two spontaneous or induced sputum samples and a specimen of tissue or cerebrospinal fluid (if clinically indicated) were examined for acid-fast bacilli and cultured for mycobacteria. The Xpert MTB/RIF21 (Cepheid; Sunnyvale, CA, USA) real-time polymerase chain reaction (PCR) assay, which is a test for Mycobacterium tuberculosis and resistance to rifampin, was performed on respiratory samples in the Kenyan cohort. Whole blood was collected extracted with the use of PAXgene Blood RNA Kits (Qiagen; Venlo, the Netherlands) and analyzed on HumanHT-12 v.4 Expression BeadChip arrays (Illumina; San Diego, CA, USA).

The team identified a tuberculosis-specific transcriptome signature in host blood that appears to be valuable in distinguishing tuberculosis from other diseases with similar clinical features in HIV-positive and HIV-negative African children. The risk score identified higher proportions of culture-confirmed cases of tuberculosis and culture-negative cases than did the Xpert MTB/RIF assay. The risk score was also more sensitive than the interferon-γ–release assay (IGRA) and the C-reactive protein level proved to be a poor biomarker of childhood tuberculosis. By looking at 51 specific genes in the blood of children with TB, the disease can be identified in 80% of cases.

The authors concluded that the translation of transcriptional signatures into diagnostic tools in resource-poor communities will be challenging and innovation will be needed to reduce the cost and complexity of the current methods used to detect multiple RNA transcripts. The development of a test based on this risk score for tuberculosis could improve the diagnosis and surveillance of childhood tuberculosis in areas with a high or low burden of disease. The study was published on May 1, 2014, in the New England Journal of Medicine.

Related Links:

Imperial College London
Cepheid
Qiagen




Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
ESR Analyzer
miniiSED™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.